{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:04:08Z","timestamp":1792213448382,"version":"4.4.0"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Central molecular mediators\u2014including hypoxia-inducible factors (HIF-1\u03b1\/HIF-2\u03b1), MYC, wild-type and mutant p53, NF-\u03baB, STAT3, SREBPs, NRF2, and KRAS\u2014orchestrate these pathways by linking nutrient availability to oncogenic signalling, epigenetic reprogramming, and immune-metabolic crosstalk within the tumour microenvironment. Key metabolic enzymes including HK2, PKM2, LDH-A, IDH1\/2, GLS1, and FASN serve as direct effectors and therapeutic targets. Mitochondrial dynamics\u2014biogenesis (PGC-1\u03b1), fission (DRP1), fusion (MFN1\/2, OPA1), and mitophagy (PINK1-Parkin)\u2014constitute a critical regulatory layer. The bidirectional epigenetic-metabolic axis, mediated by acetyl-CoA, SAM, \u03b1-ketoglutarate, 2-hydroxyglutarate, and lysine lactylation, amplifies oncogenic transcriptional programs and locks cells into malignant states. Central to this review is the thesis that metabolic plasticity\u2014the capacity of cancer cells to dynamically switch between and co-opt multiple metabolic programs\u2014is the primary driver of tumour progression, immune evasion, and resistance to therapy. Understanding and targeting this plasticity represents the central translational challenge of cancer metabolic oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive narrative literature review was conducted across PubMed, Scopus, and Web of Science (2015\u20132025) using terms including metabolic reprogramming, Warburg effect, oncometabolites, mitochondrial dynamics, epigenetic metabolism, immunometabolism, and metabolic therapeutics. Peer-reviewed primary research and comprehensive reviews were evaluated. Limitations include restriction to English-language literature (2015\u20132025), potential publication bias toward high-impact journals, and the rapidly evolving nature of the field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Metabolic reprogramming is governed by an interconnected network of transcription factors, signalling cascades, epigenetic regulators, mitochondrial dynamics, and TME-immune crosstalk. FDA-validated targets include IDH1\/2 (ivosidenib, enasidenib, vorasidenib\u2014August 2024), HIF-2\u03b1 (belzutifan), and mTOR (everolimus). An expanding clinical pipeline encompasses GLS1, MCT1, OXPHOS Complex I, FASN, and metabolic immune checkpoints. Future advances require single-cell\/spatial metabolomics, AI-driven patient stratification, and rational combination strategies that preempt adaptive metabolic escape. Future advances require AI-driven genome-scale metabolic modelling for patient stratification, single-cell and spatial metabolomics to resolve intra-tumoral metabolic heterogeneity, and rational combination strategies targeting multiple metabolic nodes simultaneously to preempt adaptive resistance. Integration of circadian pharmacology, host metabolic comorbidity management (obesity, diabetes, gut microbiome modulation), and TME metabolic normalisation into cancer treatment frameworks will drive the next generation of precision metabolic oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1897564","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:26:41Z","timestamp":1785212801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Host systemic metabolism and cancer metabolic vulnerabilities: mechanisms and therapeutic opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Rashid","family":"Mir","sequence":"first","affiliation":[{"name":"Prince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk","place":["Tabuk, Saudi Arabia"]},{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Barnawi","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseh A","family":"Algehainy","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]},{"name":"Prince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"M. Jalal","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik A.","family":"Altayar","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema M","family":"Almotairi","sequence":"additional","affiliation":[{"name":"Prince Fahad Bin Sultan Chair for Biomedical Research, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris J","family":"Tayeb","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdoh S","family":"Moawadh","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqaiah I","family":"Bedaiwi","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholoud S.","family":"Almasoudi","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Altedlawi","family":"Albalawi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Faculty of Medicine, University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alasmari","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, College of Medicine, University of Bisha","place":["Bisha, Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Muzaffar","family":"Mir","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, College of Medicine, University of Bisha","place":["Bisha, Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63852","article-title":"Hypoxia-inducible factor 1-alpha (HIF-1\u03b1): an essential regulator in cellular metabolic control","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115064","article-title":"Metabolic reprogramming, sensing, and cancer therapy","volume":"43","author":"Mao","year":"2024","journal-title":"Cell Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumours in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J Gen Physiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1042\/bst20160094","article-title":"The Warburg effect: 80 years on","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s42255-023-00963-z","article-title":"Metabolic heterogeneity in cancer","volume":"6","author":"Demicco","year":"2024","journal-title":"Nat Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2977\/MK-6482 (belzutifan)","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor","volume":"62","author":"Xu","year":"2019","journal-title":"J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcdb.2015.08.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121584","article-title":"Targeting mTOR and metabolism in cancer: lessons and innovations","volume":"8","author":"Magaway","year":"2019","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-11-36","article-title":"LKB1 and AMPK and the cancer-metabolism link \u2014 ten years after","volume":"11","author":"Hardie","year":"2013","journal-title":"BMC Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molcel.2017.05.032","article-title":"AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance","volume":"66","author":"Garcia","year":"2017","journal-title":"Mol Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0582-8","article-title":"The ERK and JNK pathways in the regulation of metabolic reprogramming","volume":"38","author":"Papa","year":"2019","journal-title":"Oncogene"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: from bench to bedside","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: a master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1242\/dev.102376","article-title":"The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease","volume":"141","author":"Varelas","year":"2014","journal-title":"Development"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.10.034","article-title":"Characterization of Hippo pathway components by gene inactivation","volume":"64","author":"Plouffe","year":"2016","journal-title":"Mol Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.08.013","article-title":"Mechanisms and implications of metabolic heterogeneity in cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Cell Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113244","article-title":"Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment","volume":"12","author":"P\u00e9rez-Tom\u00e1s","year":"2020","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2014.06.005","article-title":"The pentose phosphate pathway and cancer","volume":"39","author":"Patra","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010124","article-title":"Energy metabolism in cancer: the roles of STAT3 and STAT5","volume":"12","author":"Valle-Mendiola","year":"2020","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101073","article-title":"Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumours","volume":"25","author":"Lee","year":"2019","journal-title":"Redox Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7150\/thno.53417","article-title":"c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation","volume":"11","author":"Tang","year":"2021","journal-title":"Theranostics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1130747","article-title":"Key events in cancer: dysregulation of SREBPs","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2004.09.018","article-title":"SREBP transcription factors: master regulators of lipid homeostasis","volume":"86","author":"Eberl\u00e9","year":"2004","journal-title":"Biochimie"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature24057","article-title":"Glucose feeds the TCA cycle via circulating lactate","volume":"551","author":"Hui","year":"2017","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","article-title":"Targeting mitochondria metabolism for cancer therapy","volume":"11","author":"Weinberg","year":"2015","journal-title":"Nat Chem Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01013","article-title":"Why all the fuss about oxidative phosphorylation (OXPHOS)","volume":"63","author":"Xu","year":"2020","journal-title":"J Med Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial metabolism as a target for cancer therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00280-026-04894-w","article-title":"Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review","volume":"96","author":"Aruchamy","year":"2026","journal-title":"Cancer Chemother Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.85","article-title":"Altered metabolite levels in cancer: implications for tumour biology and cancer therapy","volume":"16","author":"Sullivan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18073575","article-title":"Expanding roles of de novo lipogenesis in breast cancer","volume":"18","author":"Simeone","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032652","article-title":"The role of PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma metabolism","volume":"24","author":"Tian","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.06.014","article-title":"Hexokinase 2 is required for tumor initiation and maintenance","volume":"24","author":"Patra","year":"2013","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666181213092652","article-title":"Unlocking the potential of HK2 in cancer metabolism and therapeutics","volume":"26","author":"Garcia","year":"2019","journal-title":"Curr Med Chem"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2023.100077","article-title":"Hexokinases in cancer and other pathologies","volume":"2","author":"Guo","year":"2023","journal-title":"Cell Insight"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00159","article-title":"Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis","volume":"10","author":"Zahra","year":"2020","journal-title":"Front Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Anastasiou","year":"2012","journal-title":"Nat Chem Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114504","article-title":"The role of metabolic reprogramming of tumour-associated macrophages","volume":"161","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41392-022-01151-3","article-title":"Lactate metabolism in human health and disease","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-020-00228-7","article-title":"The usefulness of lactate dehydrogenase measurements in current oncological practice","volume":"25","author":"Forkasiewicz","year":"2020","journal-title":"Cell Mol Biol Lett"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.11.007","article-title":"Role of LDH in tumour glycolysis: regulation of LDHA by small molecules","volume":"87","author":"Sharma","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177606","article-title":"Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models","volume":"134","author":"Verma","year":"2024","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107437","article-title":"Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer","volume":"209","author":"Hao","year":"2024","journal-title":"Pharmacol Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy)","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100469","article-title":"Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations","volume":"2","author":"Hvinden","year":"2021","journal-title":"Cell Rep Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO)","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.130","article-title":"Therapeutic strategies impacting cancer cell glutamine metabolism","volume":"5","author":"Lukey","year":"2013","journal-title":"Future Med Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01398","article-title":"Discovery of IPN60090, a clinical stage selective GLS-1 inhibitor","volume":"63","author":"Soth","year":"2020","journal-title":"J Med Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.05.013","article-title":"Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses MYC-driven medulloblastoma","volume":"12","author":"Hanaford","year":"2019","journal-title":"Transl Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-12-0095","article-title":"ATP citrate lyase knockdown induces growth arrest and apoptosis","volume":"11","author":"Zaidi","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","article-title":"NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications","volume":"5","author":"Ju","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4062\/biomolther.2017.185","article-title":"Metabolic signaling to epigenetic alterations in cancer","volume":"26","author":"Kim","year":"2018","journal-title":"Biomol Ther (Seoul)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-biochem-030122-044718","article-title":"Moonlighting enzymes at the interface between metabolism and epigenetics","volume":"94","author":"van der Knaap","year":"2025","journal-title":"Annu Rev Biochem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/freae.2024.1451971","article-title":"Subcellular one carbon metabolism in cancer, aging and epigenetics","volume":"2","author":"Bernasocchi","year":"2024","journal-title":"Front Epigenet Epigenomics"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891018","article-title":"Comparing DESI-MSI and MALDI-MSI mediated spatial metabolomics in cancer","volume":"12","author":"He","year":"2022","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-018-0023-y","article-title":"Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes","volume":"25","author":"Poepsel","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"eBioMedicine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12943-025-02407-6","article-title":"Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy","volume":"24","author":"Lv","year":"2025","journal-title":"Mol Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12051075","article-title":"PGC-1\u03b1 is a master regulator of mitochondrial lifecycle and ROS stress response","volume":"10","author":"Abu Shelbayeh","year":"2023","journal-title":"Antioxidants"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0092-0","article-title":"Mitochondrial proteins: from biogenesis to functional networks","volume":"20","author":"Pfanner","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0949-5","article-title":"Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells","volume":"38","author":"Han","year":"2019","journal-title":"Oncogene"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407043101","article-title":"OPA1 requires mitofusin 1 to promote mitochondrial fusion","volume":"101","author":"Cipolat","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","article-title":"The mitophagy pathway and its implications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00721-w","article-title":"Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma","volume":"5","author":"Mahmood","year":"2024","journal-title":"Nat Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.08.001","article-title":"Mitochondrial DNA is a major source of driver mutations in cancer","volume":"8","author":"Kim","year":"2022","journal-title":"Trends Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00018-025-05812-8","article-title":"Ferroptosis in cancer: revealing the multifaceted functions of mitochondria","volume":"82","author":"Ding","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1220744","DOI":"10.4324\/9780429461002","article-title":"Artificial intelligence vs. evolving super-complex tumour intelligence","volume":"6","author":"Sharma","year":"2023","journal-title":"Front Artif Intell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.70","article-title":"The biological essence of synthetic lethality: new opportunities for cancer therapy","volume":"3","author":"Ge","year":"2024","journal-title":"MedComm Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1511560","article-title":"Expanding horizons of cancer immunotherapy: hopes and hurdles","volume":"15","author":"Sonar","year":"2025","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.016","article-title":"An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis","volume":"162","author":"Birsoy","year":"2015","journal-title":"Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12032-022-01724-w","article-title":"The immunosuppressive role of indoleamine 2,3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies","volume":"39","author":"Hosseinalizadeh","year":"2022","journal-title":"Med Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010179","article-title":"Metabolic implications of immune checkpoint proteins in cancer","volume":"11","author":"Stirling","year":"2022","journal-title":"Cells"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010181","article-title":"In vivo anticancer activity of AZD3965: a systematic review","volume":"27","author":"Silva","year":"2021","journal-title":"Molecules"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00210","article-title":"Exploring monocarboxylate transporter inhibition for cancer treatment","volume":"5","author":"Koltai","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic heterogeneity in human lung tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.5c02598","article-title":"Curcumin-Integrated Smart Nanocarriers: A Multi-Stimuli-Responsive Platform for Targeted Delivery of 5-Fluorouracil in Cancer Therapy","volume":"9","author":"Kikani","year":"2026","journal-title":"ACS Appl Bio Mater"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-61444-3","article-title":"Metformin-restricted motility of an NRF2-activated lung cancer cell line involves NAD+ depletion, rather than AMPK- or BACH1 signaling","author":"Cabrera","year":"2026","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0008","article-title":"Biomarkers of dietary energy restriction in women at increased risk of breast cancer","volume":"2","author":"Ong","year":"2009","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:26:43Z","timestamp":1785212803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":110,"alternative-id":["10.3389\/fonc.2026.1897564"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897564","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1897564"}}